Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
BACKGROUND
It has been demonstrated that neutrophil:lymphocyte (NLR) and platelet:lymphocyte (PLR) ratios are associated with prognosis in cancer patients. The aim of this study was to investigate whether pretreatment white blood cell (WBC), neutrophil, lymphocyte, monocyte, platelet, basophil and eosinophil counts, LDH level, NLR and PLR are associated with prognosis in patients with malignant pleural mesothelioma (MPM).


METHODS
We retrospectively reviewed files of 50 patients who were managed with a diagnosis of MPM between 2005 and 2010. Demographic and clinical characteristics, treatments, response to treatment and prognostic factors were evaluated, along with relationships between pretreatment blood parameters and prognosis.


RESULTS
Overall, 38 men and 12 women were included to the study. Mean age was 61.5±9.4 years (range: 39-83 years). There was advanced disease in 86% (n=43) and the histological type was epithelial mesothelioma in the majority (82%). Of the cases, 17 (34%) received radiotherapy, while 42 cases underwent first- and second-line chemotherapy, with cisplatin plus pemetrexed as the most commonly used regimen. In the assessment after therapy, it was found that there was complete response in 4 cases (8%), partial response in 10 cases (20%), stable disease in 17 cases (34%) and progression in 19 cases (38%). Median follow-up was 10 months (range: 10 day-30 months). Median overall survival was found to be 20.7 months while median progression-free survival as 10 months. In univariate and multivariate analyses, it was found that factors significantly affecting overall survival included stage (p=0.030), response to treatment (p=0.026) and monocyte count (p=0.004), while factors affecting disease-free survival included NLR (p=0.018), response to treatment (p=0.001), and PLR score (p=0.003).


CONCLUSIONS
Overall and disease-free survival was found to be better in cases with a WBC count<8.000, platelet count<300,000, and low NLR and PLR scores in malignant pleural mesothelioma.
Department of Radiation Oncology, Kayseri Education and Research Hospital, Kayseri, Turkey E-mail : cihany@erciyes.edu.tr.
Yasemin Benderli
YB
Cihan
Ahmet
A
Ozturk
Hasan
H
Mutlu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005971:Glutamates / Q000008:administration & dosage; D006098:Granulocytes / Q000187:drug effects / Q000473:pathology; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007958:Leukocyte Count / Q000379:methods; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000473:pathology*; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology*; D000068437:Pemetrexed; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies
D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D002945:Cisplatin